Company · founded 1986
Therapeutics Systems Research Laboratories (United States)
Ann Arbor, United States · tsrlinc.com
- Citations, last 5 years
- 59
- Works, last 5 years
- 12
- h-index
- 50
- Scientists listed
- 2
- Grants since 2016
- 29
Grants received
2024–2026 · research · R44
Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2024–2025 · cooperative agreement · U44
Phase 1 Clinical Trial to Assess the Pharmacokinetics, Safety and Tolerance of a Zanamivir Transdermal System in Healthy Subjects
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2024–2027 · research · R44
Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2023–2024 · research · R44
Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2022–2024 · research · R43
Novel, Safe, Efficacious Heparin Reversal
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2022–2024 · research · R44
Development of Synthetic High-Density Lipoproteins for Treatment of Sepsis
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2022–2024 · research · R44
Development of Synthetic High-Density Lipoproteins for Treatment of Sepsis
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2022–2024 · research · R43
Microneedle Delivery of Trospium Chloride Optimized for Improved Tolerance and Patient Outcomes in Overactive Bladder Disease
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2022–2027 · research · R44
Microneedle delivery of Trospium Chloride optimized for improved tolerance and patient outcomes in overactive bladder disease
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2019–2021 · research · R41
A Novel Combination Therapy to Treat Biofilm-based Pneumonia Infections
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2019–2021 · research · R41
A Novel Combination Therapy to Treat Biofilm-based Pneumonia Infections
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2018–2020 · research · R03
New Prodrug Strategies for Cidofovir Designed for Mitigating First-Pass Metabolism
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2018–2020 · research · R03
New Prodrug Strategies for Cidofovir Designed for Mitigating First-Pass Metabolism
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2017–2026 · research · R44
Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2017–2020 · research · R44
Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2017–2025 · research · R44
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2017–2026 · research · R44
Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2017–2020 · research · R44
Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2017–2019 · research · R43
Microneedle Delivery of Zanamivir for Treatment of Influenza Infections
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2017–2019 · research · R43
Microneedle Delivery of Zanamivir for Treatment of Influenza Infections
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2017–2021 · research · R44
Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2017–2025 · research · R44
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2017–2020 · research · R41
Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2017–2019 · research · R41
Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2017–2022 · research · R44
Microneedle Delivery of Zanamivir for Treatment of Influenza
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2017–2022 · research · R44
Microneedle Delivery of Zanamivir for Treatment of Influenza
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2017–2025 · research · R44
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2017–2022 · research · R44
Microneedle Delivery of Zanamivir for Treatment of Influenza
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health
2017–2026 · research · R44
Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.
Elke Lipka · Therapeutics Systems Research Laboratories (United States) · funded by National Institutes of Health